Suppr超能文献

晚期乳腺癌患者行降险手术的挑战与考虑

Challenges and Considerations on Risk-Reducing Surgery in Patients with Advanced Breast Cancer.

机构信息

Medical Oncology Department, Hospital São Francisco Xavier, Centro Hospitalar Lisboa Ocidental, 1449-005 Lisboa, Portugal.

Familial Cancer Risk Clinic, Instituto Português de Oncologia de Lisboa Francisco Gentil, 1099-023 Lisboa, Portugal.

出版信息

Curr Oncol. 2021 Jan 14;28(1):485-490. doi: 10.3390/curroncol28010050.

Abstract

Cancer survivors harboring inherited pathogenic variants in the breast cancer (BC) susceptibility genes or are at increased risk of ovarian cancer (OC) and also of contralateral BC. For these women, risk-reducing surgery (RRS) may contribute to risk management. However, women with locally advanced or metastatic breast cancer (ABC) were excluded from clinical trials evaluating the benefit of these procedures in the carriers, and thus, current guidelines do not recommend RRS in this specific setting. Although ABC remains an incurable disease, recent advances in treatment have led to increased survival, which, together with improvement in RRS techniques, raise questions about the potential role of RRS in the management of ABC patients. When should RRS be discussed as an option for patients diagnosed with ABC? To address this issue, we report two clinical cases that reflect new challenges in routine oncology practice. Team experience and patient motivations may shape multidisciplinary decisions in the absence of evidence-based data. A wise rationale may be the analysis of the competing risks of death by a previous ABC against risk of death by a secondary BC or OC, tailored to patient preferences.

摘要

携带有乳腺癌(BC)易感基因种系致病性变异或的癌症幸存者,其卵巢癌(OC)和对侧 BC 的发病风险增加。对于这些女性,降低风险的手术(RRS)可能有助于风险管理。然而,患有局部晚期或转移性乳腺癌(ABC)的女性被排除在评估这些手术在种系携带者中获益的临床试验之外,因此,目前的指南不建议在这种特定情况下进行 RRS。尽管 ABC 仍然是一种不可治愈的疾病,但治疗方面的最新进展导致了生存率的提高,这与 RRS 技术的改进一起,引发了关于 RRS 在管理 ABC 患者中的潜在作用的问题。当应该将 RRS 作为诊断为 ABC 的患者的一种选择进行讨论时?为了解决这个问题,我们报告了两个临床病例,反映了常规肿瘤学实践中的新挑战。团队经验和患者动机可能会在缺乏基于证据的数据的情况下影响多学科决策。明智的理由可能是分析先前 ABC 导致的死亡风险与继发性 BC 或 OC 导致的死亡风险之间的竞争,这需要根据患者的偏好进行调整。

相似文献

8

本文引用的文献

7
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.恩美曲妥珠单抗治疗既往 HER2 阳性乳腺癌。
N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验